Clinical chemistry最新文献

{"title":"B-327 Measurable Residual Disease Monitoring at Acute Myeloid Leukemia Based on Laboratory Data","authors":"Soraya Andrade, Julia Marini, Andressa Vaz, Karina Lacerda, Sueli Yogui, Perla Vicari, Graziele Ferreira, Debora Ramadan, Sergio Tufik, Vitor Queiroz","doi":"10.1093/clinchem/hvaf086.714","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf086.714","url":null,"abstract":"Background Measurable Residual Disease (MRD) is an important biomarker at Acute Myeloid Leukemia (AML) monitoring, prognosis, predictor of recurrence and guidance of treatment decisions. Different techniques were available to MRD analysis, such as: RT-qPCR/digital droplet PCR, Next Generation Sequency and Multiparametric Flow Cytometry (MFC), through immunophenotyping of abnormal cell population. The MFC is an essential tool for studying the cell lineages involved in AML. The LAIP characterization (Leukemia-associated immunophenotypes) at the diagnosis moment is critical to establish the best strategy reproducible to the MRD study. This study aimed to analyze the immunophenotyping data from patients with AML diagnoses, based on laboratory MRD exams. Methods A retrospective analysis was performed using MRD immunophenotyping data from bone marrow (BM) and peripheral blood (PB) samples of patients diagnosed with AML in the internal database of a clinical laboratory in São Paulo, Brazil, between September 2023 and November 2024. MRD analyses were performed by MFC using an internal standardized marker panel. The analyses strategies used were maturation different from normal (DfN) and LAIP. Data analysis included: age, gender, number of patients, test results, sample type and LAIP frequency. Results MRD tests were performed for 62 patients, of which 56% (35/62) are female, with the highest incidence in those = 50 years, accounting for 28 (45.2%) cases. Of these, 42 patients have a diagnosis analyzed in our service. Each patient had between one and seven MRD tests during treatment monitoring, totaling 146 MRDs analyzed. The gold standard material for MRD testing is BM; however, 9.6% (14/146) of the MRDs were performed using PB. Of the 62 patients, 48.4% (30/62) were negative on the first MRD, 9.7% (6/62) on the second, 1.6% (1/62) on the third, and 1.6% (1/62) on the fourth, highlighting a group of patients who respond to treatment. 21% (13/62) of the patients tested positive for MRD, even after one to four negative tests, with blast percentages ranging from 0.09% to 19.04%, indicating a group of patients with relapse disease. 17.7% (11/62) of the patients remained with positive MRD results, demonstrating a group of patients possibly refractory disease. About the LAIPs of lineage infidelity, they were found in 40.4% (76/188) of the cases, considering diagnosis and follow-up, with frequencies of CD123 (41.9%), CD7 (25.6%), CD56 (19.8%), CD2 (7%), and CD19 (5.8%). In an analysis focused on patients, 31 (50%) patients presented at least one type of LAIPs. Conclusion MRD analysis is essential for monitoring AML and has been employed in clinical trials of new agents and emerging therapies for AML. Among the techniques available for MRD research, immunophenotyping by MFC has advantages such as broad applicability, accessibility, turnaround time, specificity, and lower cost comparable to other techniques.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"101 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-290 A perspective on commonly used drugs in patients receiving treatment for opioid use disorder in Ontario, Canada","authors":"Josko Ivica, Aariz Naeem, Jacqueline Hudson, Matthew Nichols, Eleonora Petryayeva, Joseph Macri, Alannah McEvoy, Zainab Samaan","doi":"10.1093/clinchem/hvaf086.677","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf086.677","url":null,"abstract":"Background Urine drug screens (UDS) are limited to a few drug classes of interest and are typically done by immunoassay-based (IA) methods. Screening results can then be confirmed by liquid chromatography coupled with tandem mass spectrometry methods (LC-MS/MS) if required. Medication-assisted treatment (MAT) has been used for treatment and monitoring of Opioid Use Disorders (OUD). Medications used in MAT are usually methadone and/or a combination of buprenorphine and naloxone. The aim of this is study was to see what other drugs the participants from the Pharmacogenetics of Opioid Substitution Treatment Response (POST) study in Ontario, Canada, were taking in addition to the prescribed medications. Methods Two hundred POST study participants provided their urine samples to be tested on LC-MS/MS after their urines had been screened by IA. There were 99 drugs tested in this method. The kits were provided by Chromsystems (Grafelfing, Germany) and we followed their procedure for the analysis of these drugs. We investigated the participants’ demographics by age and gender/sex, the most commonly used drugs, their most common combinations, and the number of participants who were taking = 2 drugs, confirmed by LC-MS/MS. We also checked discordances between IA and LC-MS/MS for MATs, and amphetamine and methamphetamine. All the analyses and pertaining graphs were done in Microsoft Excel (Microsoft Corporation). Results The average age for all participants was 39.5 years. The participants were divided into 5 age groups (20-29.9, 30-30.9, 40-49.9, 50-50.9, = 60) and two sexes (males and cis/trans-females). Majority (n=161, 80.5%) of the participants were of the European descent, and 43.0 % were females. The three most commonly abused drugs were selected for a more detailed demographics analysis: THC-COOH (n=96, 48%), amphetamine and methamphetamine (n=47, 23.5%, for both). THC-COOH was present in 11.5% participants aged 20-29.9, 16.5% aged 30-39.9, 10% aged 40-49.9, 8% aged 50-59.9 and 2% = 60 years of age. THC-COOH was present in 31.5% males and 16% females (0.5% trans-females). Both amphetamine and methamphetamine were present in 23.5% of the participants (n=47), and both were present in 15% males and 8.5% females, as expected. There was only a slight difference between age groups. The percentage of the most common drug combination was as follows: amphetamine and methamphetamine (42%); amphetamine, methamphetamine combined with THC-COOH (19%); and amphetamine, methamphetamine combined with norfentanyl (18%). The greatest number of participants who took = 2 drugs confirmed by LC-MS/MS (n=40, 20%) had 3 drugs in urine. Surprisingly, 26.5% of participants who were compliant with their MATs, confirmed by LC-MS/MS, were negative on IA screens. Thirty-one participants (15.5%) were falsely positive for either amphetamine or methamphetamine on IA, after being confirmed negative on LC-MS/MS. Conclusion This work has shed important light into what populations acros","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"32 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A-185 Stacking Credentials: Advancing Careers and Highlighting Professional Expertise with ASCP BOC Credentials","authors":"Joseph Baker","doi":"10.1093/clinchem/hvaf086.179","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf086.179","url":null,"abstract":"Background Laboratory professional credentials attained through the ASCP Board of Certification (ASCP BOC) play a pivotal role in addressing this challenge. By standardizing and enhancing the professional skills of laboratory professionals, ASCP BOC credentials open new avenues for recruitment, retention, and professional development. Stacking credentials, such as pairing Medical Laboratory Scientist, MLS(ASCP) with Specialist in Blood Banking, SBB(ASCP)or other specialized credentials, has emerged as a significant pathway for career growth, skill enhancement, and clear career progression. This study explores how credential stacking enhances individual expertise, supports career advancement, and contributes to creating a skilled and satisfied workforce, ultimately addressing operational challenges and workforce shortages in laboratory settings. Methods This study utilized a comprehensive analysis of ASCP BOC’s credentialing data, focusing on individuals with multiple credentials. Data were segmented by degree (e.g., Bachelor’s, Master’s, PhD), credential count (ranging from 2 to 10), and professional demographics. The analysis also included geographical distribution across the U.S. and internationally to identify patterns and growth trends. Metrics analyzed included the number of professionals holding multiple credentials, time elapsed between the attainment of the first and subsequent credentials and associated professional outcomes. In addition to credentialing data, insights from health and business literature were reviewed to contextualize the findings and explore intentional workforce strategies. Results The data revealed that approximately 9.7% of ASCP BOC credential holders now possess two or more credentials. Credential stacking demonstrates measurable benefits for professionals and employers alike, supporting continuous professional development and specialization. Key findings:Earning Potential: Research has shown stacked credential holders may see as much as a 9% return on average in their salaries.Workforce Strategies: Credential stacking supports clear career progression pathways and continuous professional development, which help attract new talent and retain skilled staff. These strategies foster a positive workplace culture, promote work-life balance, and contribute to greater employee satisfaction.Professional Skills Enhancement: Credential holders with stacked credentials demonstrated consistent scaled score performance (mean = 475), reflecting sustained professional excellence.Operational Impact: Employers noted increased versatility, leadership readiness, and adaptability among multi-credentialed professionals, particularly in specialized laboratory roles.Geographical analyses highlighted hotspots for laboratory professionals seeking multiple credentials in both domestic U.S. regions and internationally. These findings suggest that the ASCP BOC, and by extension the broader laboratory medicine and pathology community, can great","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"3 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-303 Validation of a New Benzodiazepine Immunoassay with Improved Detection of Glucuronidated Benzodiazepines","authors":"Imir Metushi","doi":"10.1093/clinchem/hvaf086.690","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf086.690","url":null,"abstract":"Background The new Roche benzodiazepines II immunoassay utilizes an on board beta-glucuronidase enzyme that should enhance detection of glucuronidated benzodiazepines. We evaluated and validated this new assay across three laboratory testing sites: 1) a community hospital, 2) a quaternary-care medical center and a 3) outreach reference laboratory. Methods The new ONLINE DAT Benzodiazepines II immunoassay (IMA) utilizes the same calibrators and controls as its predecessor but it includes a ß-glucuronidase enzyme in one of its reagents. This addition should help hydrolize glucuronide from its benzodiazepine conjugates and improve the detection of benzodiazepine glucuronides. Any samples that were discordant were run by liquid chromatography-mass spectrometry for confirmation. We tested the precision of the immunoassay systems by taking a positive and negative sample and running over a total of 20 runs. We tested 120 patient samples using both the current Benzodiazepine Plus and the new Benzodiasepines II immunoassays across three laboratory testing sites. The cut off used for a positive result was 200 ng/mL. A query was conducted to review the number of positive and negative benzodiazepine results 3 months prior to converting to the Benzodiazepine II version of the assay and 3 months after. Results The assay was precise 100% of the times using both negative and positive samples across all three- testing sites. A total of 59 positive samples and a total of 61 negative samples by the old Benzodiazpines II immunoassay were used for patient correlation. The 59 positive samples using the old Benzodiazepine plus immunoassay were also positive by the new Bensoziazepine II immunoassay. We noticed that from the 61 negative samples as classified by the old Benzodiazepine Plus immunoassay, 8 samples tested positive when run on the new Benzodiasepine II immunoassay. These 8 samples were confirmed by mass spectrometry to be true positive. We noticed that the 8 true positive samples had the following analytes: Sample 1, alprazolam at 59 ng/mL and a-OH alprazolam at 64 ng/L; Sample 2, alprazolam at 99 ng/mL and a-OH alprazolam at 36 ng/mL; Sample 3, a-OH midazolam at 377 ng/mL; Sample 4, lorazepam at 650 ng/mL; Sample 5, lorazepam at 370 ng/mL; Sample 6, lorazepam at 1659 ng/mL; Sample 7, lorazepam at 726 ng/mL; Sample 8, lorazepam at 34 ng/mL, alprazolam at 22 ng/mL, a-OH alprazolam at 17 mg/mL, 7-aminoclonazepam at 241 ng/mL. Our query identified that in the prior month before converting to Benzodiazepine Plus IMA the rate of positive Benzodiazepine IMA screens was 8%, and 3 months after converting to the Benzodiazepine Plus IMA the rate of a positive benzodiazepine screen increased to 15%. Conclusion Our results indicate that the new version of the assay, by using the addition of the on board hydrolysis step with beta glucuronidase greatly enhances the detection rate of benzodiazepines.","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"101 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-241 Stabilization of Probe qPCR Mix: A Comparison of Capillary-Assisted Vitrification and Lyophilization","authors":"Sankar Renu, Yolanda Peris-Taverner, Matthew Carroll, Mary Shank-Retzlaff, Laura Bronsart, Pravansu Mohanty","doi":"10.1093/clinchem/hvaf086.629","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf086.629","url":null,"abstract":"Background qPCR master mixes are formulated for high specificity, sensitivity, and the reproducible diagnosis of diseases. However, traditional frozen master mixes have limitations, including strict transportation, storage, and usage conditions, which can impact their performance. Recent advancements in lyophilization (freeze-drying) have led to the creation of lyophilized bead or cake master mix products. Lyophilized qPCR master mixes offer benefits such as long shelf life and room-temperature storage, but they come with challenges. These include instability of certain components, the need for complex optimization, longer drying cycle, and increase costs. To tackle the challenges of lyophilization, we introduced capillary-assisted vitrification (CAV) processes, which can stabilize different biomolecules within an hour, with little to no optimization, and allow for storage at ambient temperature. In this comparison study, we evaluated the linearity, efficiency, analytical sensitivity, specificity, and stability of lyophilized and CAV-stabilized TaqMan probe qPCR mix. Methods The lyophilized PrimePath Probe qPCR mix was purchased from Takara Bio, stored at room temperature, and used as per the recommendation. For CAV sample preparation, 5X PrimePath Probe qPCR mix from Takara Bio was combined with Ambient BioFix buffer, applied to the Ambient BioFix scaffold, and desiccated for 30 minutes using the Ambient stabilizer. The stabilized mix was either used immediately or stored in Ambient storage bags. For stability testing, both lyophilized and CAV-stabilized samples were stored at 37°C for 2 months and 50°C for 1 month. On the testing day, lyophilized and CAV samples were rehydrated, and monkeypox virus (MPXV) primers, probes, and synthetic DNA were mixed and tested using the QuantStudio 5 Real-Time PCR System. Results To evaluate the performance of lyophilized and CAV-stabilized qPCR mixes, the linearity and efficiency of the stabilized reagents were tested using fivefold serial dilutions of MPXV DNA. Both reagents demonstrated similar coefficients of determination (R² = 0.99), with amplification efficiencies of 99% for the lyophilized sample and 105% for the CAV sample, both within the acceptable range for the assay. The analytical limit of detection (LOD) was 5 copies/reaction for the CAV sample and 10 copies/reaction for the lyophilized sample. As expected, both lyophilized and CAV-stabilized reagents showed undetermined cycle threshold (Ct) values when no template was used. Additionally, comparable amplification and Ct values (20 and 21) were observed for both lyophilized and CAV-stabilized samples when stored at 37°C for 2 months and 50°C for 1 month. Conclusion With little to no optimization and a one-hour cycle time, the qPCR mix was successfully stabilized using the CAV process without freezing. Its performance and stability were comparable to that of lyophilized mixes. The study recommends the CAV process as an alternative to complex lyoph","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"2 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-324 Prevalence of high phosphatidylethanol (PEth) concentrations in a blood transfusion product","authors":"Grace Williams, Jordan Keller, Vipulkumar Prajapati, Regina DelBaugh, Kimberly Sanford, Justin Poklis, Carrol Nanco, Carl Wolf","doi":"10.1093/clinchem/hvaf086.711","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf086.711","url":null,"abstract":"Background Recent publications have demonstrated the possibility of false-positive 16:0/18:1 phosphatidylethanol (PEth) testing results due to the presence of PEth in blood transfusion products. PEth biomarker results are used to evaluate individuals for ethanol abstinence in a variety of clinical settings. PEth positivity in individuals expected to abstain from alcohol can have serious legal and clinical consequences. Little is known about the prevalence of donated blood products with a high enough PEth concentration to cause a false-positive result in a a patient who receives a transfusion. The Blood Donor History Questionnaire does not ask about ethanol use. Packed red blood cells (pRBC) are the most commonly stored and used blood component in blood banks. To assess the prevalence of clinically significant PEth concentrations, 400 residual pRBC segments samples were analyzed and the concentration of PEth was quantified. Current clinical interpretation is that >20 ng/mL PEth concentration indicates moderate alcohol consumption. Methods A liquid-chromatography tandem mass spectrometry (LC-MS/MS) method was validated using a Waters TQS micro triple quadrupole in whole blood or pRBC. In brief, PEth and the internal standard PEth 16:0/18:1-D5 were obtained from Cerilliant. Calibrators and QC materials were made from separate, recently expired (<2 weeks), and PEth negative units of pRBCs. Chromatography mobile phase A was 2 mM ammonium acetate and mobile phase B was methanol/acetone (95/5). pRBC lysing buffer was 100 µL of H2O:ACN (80:20 v/v) and elution buffer is 5% IPA in ethyl acetate. The reconstitution solvent consisted of isopropanol. Analysis is conducted using a Phenominex Luna Phenyl Hexyl column. The mass spectrometer was operated in selected reaction monitoring (SRM) mode and used MassLynx Software for acquisition and analysis. The detector signal was integrated using a linear calibration curve and 1/x weighting. Compounds were identified by retention time, relative retention time to a deuterated internal standard, and SRM ion pair ratios. The LC-MS/MS validation assessed linearity, bias, recovery, precision, interferences, matrix effects, and carry-over. 400 deidentified, previously transfused pRBC unit tube segments were analyzed according to the protocol developed during validation. Using calculations corrected for average hematocrit, a single unit transfusion of pRBC containing a PEth concentration of >350 ng/mL could potentially result in a patient PEth result >20 ng/mL. Thus, 350 ng/mL in a pRBC segment was used as the criteria for clinical significance. Results Out of 400 tested pRBC segments, 185(46%) were PEth positive above the assay LOQ of 10 ng/mL. Out of the 400 pRBC segments, 33 (8%) had a PEth concentration >350 ng/mL. A pRBC unit value of >350 ng/mL could potentially result in a PEth result >20 ng/mL from a single unit transfusion. Conclusion Of the tested pRBC segments, 8% ","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"39 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145203690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retiring Friedewald, Rethinking Direct LDL-C: Modern LDL-C Equations Outperform Both the Friedewald Equation and Direct Assays.","authors":"Tahir S Pillay,Barbara S van Deventer,Siphokazi Gwiliza,Chantal van Niekerk,Patrick J Twomey","doi":"10.1093/clinchem/hvaf118","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf118","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"64 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: In Vitro Metabolic Profiling of 18 Semi-Synthetic Cannabinoids-Hexahydrocannabinol (HHC) and Its Analogs-with Identification in an Authentic Hexahydrocannabiphorol (HHCP) Urine Sample.","authors":"","doi":"10.1093/clinchem/hvaf112","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf112","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Turning Point for Lipoprotein(a) Treatment: Are Clinical Laboratories Ready?","authors":"Leslie J Donato","doi":"10.1093/clinchem/hvaf101","DOIUrl":"https://doi.org/10.1093/clinchem/hvaf101","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"57 1","pages":""},"PeriodicalIF":9.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145025486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on Complex Hyponatremia in a Cancer Patient with Hypercholesterolemia.","authors":"Gary Roulston","doi":"10.1093/clinchem/hvaf051","DOIUrl":"10.1093/clinchem/hvaf051","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"71 9","pages":"934"},"PeriodicalIF":6.3,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}